On July 17, 2019, Shanghai Longyao Biotechnology Co., Ltd. and General Electric Medical Systems Trade Development (Shanghai) Co., Ltd. ("GE Healthcare") signed a process development agreement and a strategic cooperation agreement to jointly develop autologous and allogeneic cells. Customized and multi-recombinable advanced supporting automated closed system production process to accelerate the upgrading of cell-based drugs from scientific research to industrialization. Longyao Bio's President Ye Shengqin, Vice President Fan Bin, Vice President Wang Xin, GE Healthcare's Cell Therapy Enterprise Solutions Global Business Leader Chen Qi, Asia Technical Director Ni Zhuoyu, and Sales Manager Gao Geng attended the ceremony.
Ye Shengqin, President of Longyao Biotechnology (right), signed a cooperation agreement with Chen Qi (left), Chief Global Business Leader of GE Healthcare's Cell Therapy Enterprise Solutions
At the ceremony, President Ye Shengqin welcomed GE Healthcare and his delegation, and introduced our company's achievements in the research and development and transformation of CAR-T and other immune cell technologies in recent years.
With the rise of immune cell therapy represented by CAR-T and TCR-T, the number of immune cell clinical studies has exploded with an average annual growth rate of nearly 40% in recent years. It is completely different from traditional small molecule chemical drugs and macromolecular biological drugs. The individualized cell + gene products represented by CAR-T, from GMP-grade, large-scale, high-quality plasmid and recombinant virus preparation, to the production of biopharmaceutical-grade CAR-T products, have high technological content and difficult production processes , The strict product requirements are unprecedented in the biopharmaceutical industry. Only by thoroughly improving the manual operation process in the exploratory stage of laboratory research and establishing an automated and standardized system for production, can it be possible to achieve efficient and safe clinical application trials of CAR-T products.
President Ye Shengqin said that GE Healthcare has advantages in biopharmaceutical process development, and the strong cooperation with GE Healthcare will further accelerate the pace of CAR-T drug application of Longyao Bio.
Chen Qi, Chief Global Business Leader of GE Healthcare's Cell Therapy Enterprise Solutions, introduced the project planning and future cooperation areas. Chen Qi introduced that the development project is expected to be officially delivered in October 2019. In addition to process development, GE Healthcare will also provide Longyao Bio with various GMP-compliant training services, modular cell processing equipment, automation and digital management The ability to help Longyao Biotechnology optimize its research-stage process to meet the requirements of large-scale production, and further improve efficiency in terms of simplification, integration and automation of production processes, and accelerate the clinical transformation and commercialization of its cell therapy products.
meeting venue
In the follow-up cooperation, Longyao Bio and GE Healthcare will adhere to the principle of strong alliance and complementary advantages, and jointly promote the industrialization of CAR-T cell therapy drugs in China.
Group photo of all the participants
Longyao Bio is committed to the research and development, technology transformation, product declaration, clinical application research and application promotion of tumor immune cell technology. The company is led by a strong team of scientists led by Professor Fu Yangxin and Professor Yang Xuanming of Shanghai Jiaotong University, etc., in the tumor immune CAR-T, TCR-T and other immune effector cells, immune activation cells, immune regulatory cells in the treatment of malignant hematological tumors, solid tumor technology and products. 14 product pipelines have been laid out, many original achievements have been accumulated, and a number of patents have been declared for key technologies. In July 2018, China Biotechnology Services Holdings Co., Ltd. (stock code 8037.HK) signed a contract to acquire 67% of the equity of Longyao Bio. The listed company deploys precise detection and precise treatment, and is committed to building a future biotechnology platform. In terms of funds and resources, the development of Longyao Bio is fully guaranteed.
GE Healthcare , which integrates data and data analytics in the fields of hardware, software and biotechnology, is the healthcare business unit of GE (NYSE: GE) with a business scale of $18 billion. As a leading provider of medical imaging equipment, GE Healthcare has a rich history of more than 100 years and employs more than 50,000 people in more than 100 countries around the world. The company is committed to changing the status quo in the healthcare industry by providing better service to healthcare providers and patients.